Back in December 2017, Pfizer started a trial to explore whether the PARP inhibitor talazoparib (Talzenna) could be used in combination with enzalutamide (Xtandi) to effectively treat men with what are known as MSI-H or dMMR subtypes of metastatic castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Uncategorized | Tagged: inhibitor, mCRPC, niraparib, olaparib, PARP, Phase III, rucaparib, talazoparib | 5 Comments »
According to a recent media release, a company called Endocyte has reached agreement with the US Food and Drug Administration about the design of a pivotal Phase III clinical trial that will test the effectiveness and safety of 177Lu-PSMA-617 in men with recurrent, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: efficacy, lutetium-177, outcome, Phase III, pivotal, PSMA-617, safety, trial | 4 Comments »
There are now two, ongoing, Phase III trials of PARP inhibitors in the treatment of eligible patients with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: inhibitor, mCRPC, PARP, Phase III, trial | Leave a comment »
In August we had reported on an announcement by OncoGenex Pharmaceuticals that, in the Phase III AFFINITY trial, the combination of custirsen + cabazitaxel (Jevtana) + prednisone had no significant impact on overall survival of men with metastatic, castration-resistant prostate cancer (mCRPC) who had already received first-line chemotherapy by comparison with cabazitaxel + prednisone alone. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: AFFINITY, cabazitaxel, custirsen, outcome, Phase III, trial | Leave a comment »
Back in June 2013, Johnson & Johnson acquired Aragon Pharmaceuticals and the investigational agent ARN-509 — a potential “precursor” to abiraterone acetate (see below). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ARN-509, outcome, Phase III, trial | 7 Comments »
Well, it’s taken a little over 2 years, but OncoGenex has completed enrollment of patients into the randomized, double-blind, Phase III SYNERGY trial, which is designed to assess whether the addition of custirsen (OGX-011) to docetaxel-based chemotherapy can extend the survival of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development | Tagged: custirsen, mCRPC, OGX-011, Phase III, trial | 6 Comments »
According to a number of media reports today, Medivation’s investigational drug MDV3100 appears to have a relatively good safety profile, although five patients who received MDV3100 in the completed Phase III trial did have seizures. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: efficacy, mCRPC, MDV3100, Phase III, safety | 6 Comments »
Barvarian Nordic has initiated the expected, randomized, multi-center Phase III trial of Prostvac® in men with asymptomatic and minimally symptomatic, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: mCRPC, Phase III, Prostvac, trial | 6 Comments »
Accoring to a Bloomberg Businessweek report and information on the Exelixis corporate web site, the company is planning two multi-center, randomized, Phase III clinical trials of the investigational agent cabozantinib (a.k.a., XL184) in metastatic, castration-resistant prostate cancer (mCRPC): … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: cabozantinib, mCRPC, pain, Phase III, trial | Leave a comment »
According to a media release issued earlier today, Medivation and Astellas Pharma have enrolled the first patient into a new Phase III clinical trial of MDV3100. … READ MORE …
Filed under: Drugs in development | Tagged: castration-resistant, mCRPC, MDV3100, Phase III, trial | Leave a comment »
According to an e-mail from our friends at Us TOO the AFFIRM trial (A study evaluating the eFFicacy and safety of Investigational dRug MDV3100 in men with advanced prostate cancer) has started to enroll patients in the USA. It had started to enroll patients in Europe earlier this month. … READ MORE …
Filed under: Drugs in development | Tagged: AFFIRM, MDV3100, Phase III, trial | 5 Comments »
According to a media release from Cougar Biotechnology, a second Phase III clinical trial of abiraterone acetate started today — for men with castration-resistant prostate cancer (CRPC) who have not received chemotherapy. … READ MORE …
Filed under: Drugs in development | Tagged: abiraterone acetate, CRPC, Phase III | 10 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 